Answers are grounded in this paper and cite their sources.
Study demonstrates photocatalytic efficiency of amorphous molybdenum telluride catalysts in methylene blue degradation.
To investigate the application potential of amorphous transition metal chalcogenides in catalysis, this study successfully synthesized amorphous molybdenum telluride (MoTex) materials and systematically explored their structural characteristics, compositional modulation, and catalytic performance. Experimental results indicate that the synthesized amorphous system consists of particles of approximately 200-300 nm in size. This distinct microstructure facilitates the exposure of abundant active sites and enhances physical adsorption capacity. The amorphous MoTe2/MoTe3 catalysts achieve an approximately 30%/40% degradation of methylene blue (MB) within 90 min, demonstrating significantly enhanced photocatalytic efficiency compared to that of crystalline MoTe2 (≈20% degradation under identical conditions). Furthermore, when integrated with titanium dioxide (TiO2), the composite exhibits exceptional co-catalytic performance, achieving a 90% degradation of MB within 90 min under visible-light irradiation, representing a catalytic efficiency improvement exceeding 160% compared to the results for pristine TiO2. Furthermore, through comparative analysis of the catalytic behavior and microstructural variations between amorphous MoTe3 (a-MoTe3) and MoTe2 (a-MoTe2), we observed that the catalytic activity of molybdenum tellurides exhibits a weak correlation with the tellurium content, with co-catalytic efficacy jointly governed by the density of the active sites and the physical adsorption properties. This research provides new methods and insights for the study and improvement of catalytic performance in chalcogenide materials.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: